L. Wang

759 citations

23 papers · 550 indexed · h-index 9

Impact in

Numerical Analysis top 10%
- Numerical methods for differential equations
Oncology
- Ear and Head Tumors
- Cancer Immunotherapy and Biomarkers

Papers in

Oncology 11
- Cancer Immunotherapy and Biomarkers 3
- CAR-T cell therapy research 2
Statistics and Probability 3
- Statistical Methods in Clinical Trials 3

Co-authors: A. Semlyen Susan Turner L.L. Siu Nicole G. Chau Sébastien J. Hotte Ian F. Tannock Malcolm J. Moore Anthony M. Joshua
Journals: Annals of Oncology (8 papers)Journal of Clinical Oncology (4 papers)IEEE Transactions on Power Systems (2 papers)Diabetologia (1 paper)European Journal of Cancer (1 paper)
Partner nations: Canada United States India

In The Last Decade

L. Wang

20 papers receiving 528 citations

Peers

Countries citing papers authored by L. Wang

Since Specialization

Citations

This map shows the geographic impact of L. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Wang more than expected).

Fields of papers citing papers by L. Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Wang. The network helps show where L. Wang may publish in the future.

Co-authors

The 25 scholars most cited alongside L. Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with L. Wang Line = papers co-authored together L. Wang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Histone methyltransferase DOT1L promotes myeloid-derived suppressor cell activation to ameliorate colitis by modulating JAK2/STAT3 signaling Molecular & Cellular Toxicology ·Diana Patricia Castaño López, (unknown), Rui Gong, Lin Shen, L. Wang	2025	0
2	Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients Gynecologic Oncology ·Víctor Rodríguez-Freixinós, Stéphanie Lheureux, Gourav Jain, Blaise Clarke, Neesha C. Dhani, Helen Mackay, Marcus O. Butler, L. Wang, Lillian L. Siu, Suzanne Kamel‐Reid, Tracy Stockley, Philippe L. Bédard, Amit M. Oza	2019	8
3	Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events Annals of Oncology ·Zachary Veitch, Daniel Shepshelovich, C. Gallagher, L. Wang, Albiruni Abdul Razak, Anna Spreafico, Philippe L. Bédard, Lillian L. Siu, Lori M. Minasian, Aaron R. Hansen	2019	1
4	Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer phase I IO cohort Annals of Oncology ·Daniel Vilarim Araújo, Nil Ratan SircarMedical, Dax Torti, 海上技術安全研究所推進性能部, Alberto J. León, Kayla Marsh, Aoife J McCarthy, Hal K. Berman, Anna Spreafico, Aaron R. Hansen, Albiruni Abdul Razak, Philippe L. Bédard, L. Wang, Albert Mordechai, Helen Chow, Hua Bao, Xinyao Wu, Trevor J. Pugh, Lillian L. Siu	2019	1
5	Phase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC) Annals of Oncology ·建熈梶原, Kyaw Aung, Ann McKinstry Micou, S. R. Zorin, Stefano Serra, Tracy Stockley, L. Wang, Myunsup KIM, Anna Spreafico, Aaron R. Hansen, Weixun Hu, Lillian L. Siu, Philippe L. Bédard	2019	0
6	Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials European Journal of Cancer ·Yada Kanjanapan, Daphne Day, Marcus O. Butler, L. Wang, Anthony M. Joshua, David Hogg, Natasha B. Leighl, A.R. Abdul Razak, Aaron R. Hansen, Patricia Rodriguez Unigarro, 胡浪平, G.W. Otter, B. B. Sherwin, Shcherbakov Va, D. Ratigan, E.Y. Arima, Lillian L. Siu, Philippe L. Bédard, Anna Spreafico	2018	51
7	Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC) Annals of Oncology ·Aaron R. Hansen, Ian F. Tannock, Arnoud J. Templeton, Amy Prawira, Jennifer J. Knox, Francisco Vera-Badillo, A Martorana, Edvaldo Prazeres Ramos, L. Wang, A. Evans, Dorn As, Bradly G. Wouters, Srikala S. Sridhar, Anthony M. Joshua	2016	0
8	A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer Cancer Chemotherapy and Pharmacology ·Daniel J. Renouf, David W. Hedley, Monika K. Krzyzanowska, Martin Schmuck, L. Wang, Malcolm J. Moore	2016	22
9	A Phase 1/2 Study of Ipilimumab in Women with Metastatic or Recurrent Hpv-Related Cervical Carcinoma: a Study of the Princess Margaret and Chicago N01 Consortia Annals of Oncology ·Stéphanie Lheureux, Marcus O. Butler, Gini F. Fleming, Holger W. Hirte, Mihaela Cristea, Prafull Ghatage, Lainie P. Martin, Helen Mackay, Neesha C. Dhani, Michelle Wilson, Cristina Martín-Lorente, Ma Chuan, L. Wang, Smitha Udagani, Amit M. Oza	2014	2
10	Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials Annals of Oncology ·Arnoud J. Templeton, Francisco Vera-Badillo, L. Wang, Eliane Ribeiro Dias Batista, Joo SungHyun, Raya Leibowitz‐Amit, Jennifer J. Knox, Malcolm J. Moore, Srikala S. Sridhar, Anthony M. Joshua, Gregory R. Pond, Eitan Amir, Ian F. Tannock	2013	97
11	A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC Annals of Oncology ·Nicole G. Chau, Sébastien J. Hotte, Janet Wootton, EDWARD A. BRETHAUER, Susan Turner, L. Wang, L.L. Siu	2011	112
12	Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice Diabetologia ·Xiaohong Wu, L. Wang, Stephanie A. Schroer, E.A. Derdencov, P. Chen, Chao Yu, Minna Woo	2009	22
13	Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer Annals of Oncology ·Boštjan Šeruga, 秦佩, L. Wang, Christopher M. Booth, David W. Cescon, Monika K. Krzyzanowska, Ian F. Tannock	2009	29
14	Neurocognitive outcomes of head and neck chemoradiotherapy: A pilot study Journal of Clinical Oncology ·Hui Gan, Lori J. Bernstein, LUIS A. ORTIZ ZAMORA, Jolie Ringash, Fernando Alexander Castro Carvajal, L. Wang, Brian O’Sullivan, John Waldron, Eric X. Chen, Lillian L. Siu	2009	2
15	Evolution of the randomized controlled trial (RCT) in oncology over three decades Journal of Clinical Oncology ·Christopher M. Booth, David W. Cescon, L. Wang, I. F. Tannock, Monika K. Krzyzanowska	2007	1
16	Drug interactions in ambulatory cancer patients receiving cancer-directed therapy Journal of Clinical Oncology ·Rachel P. Riechelmann, L. Wang, Ian F. Tannock, Monika K. Krzyzanowska	2006	2
17	Estimation of Process Step Response Weights based on Closed-Loop Step Response Data L. Wang, W.R. Cluett	1993	2
18	Robust Control System Design using Direct Frequency Response Raúl Andrés Alejos Vera, L. Wang, W.R. Cluett	1992	7
19	Application of sparse eigenvalue techniques to the small signal stability analysis of large power systems IEEE Transactions on Power Systems ·L. Wang, A. Semlyen	1990	115
20	Sequential computation of the complete eigensystem for the study zone in small signal stability analysis of large power systems IEEE Transactions on Power Systems ·A. Semlyen, L. Wang	1988	56

About L. Wang

L. Wang is a scholar working on Oncology, Statistics and Probability, Statistics, Probability and Uncertainty, Immunology and Numerical Analysis, having authored 23 papers that have together received 550 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (3 papers), Statistical Methods in Clinical Trials (3 papers), Control Systems and Identification (3 papers), Neuroendocrine Tumor Research Advances (2 papers), CAR-T cell therapy research (2 papers), Multiple Myeloma Research and Treatments (2 papers), Fault Detection and Control Systems (2 papers) and Power System Optimization and Stability (2 papers). The work is most often cited by research in Numerical Analysis (55 citations), Oncology (184 citations), Control and Systems Engineering (98 citations), Cancer Research (61 citations) and Otorhinolaryngology (17 citations). L. Wang has collaborated with scholars based in Canada, United States and India. Frequent co-authors include A. Semlyen, Susan Turner, L.L. Siu, Nicole G. Chau, Sébastien J. Hotte, Ian F. Tannock, Malcolm J. Moore, Anthony M. Joshua, Monika K. Krzyzanowska and W.R. Cluett. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, IEEE Transactions on Power Systems, Diabetologia and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact